Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Potent protein farnesyltransferase inhibitors emerge from Parke-Davis program

Sep. 3, 1999

Licensing opportunity from NIH: geldanamycins as inhibitors of the HGF/SF-Met pathway

Sep. 3, 1999

IGT-13, a new and improved etoposide analogue enters the IGT pipeline

Sep. 2, 1999

More ACS news: preclinical profile of a novel protein farnesyltransferase inhibitor, Sch-207758

Sep. 2, 1999

New Roche compounds enhance tumor delivery of 5-FU

Sep. 2, 1999

Cytoclonal makes strides in the design of new anticancer compounds

Sep. 2, 1999

Preparation, activity and use of piperidine protein farnesyltransferase inhibitors from LG Chemical

Sep. 2, 1999

Scotia's Foscan achieves positive results in phase III clinical trial

Sep. 1, 1999

New anticancer compound from Diatide shown to arrest tumor growth

Sep. 1, 1999

Progen receives provisional approval to undertake clinical studies of PI-88 at second site

Sep. 1, 1999

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...